Sangamo BioSciences (SGMO) Presents Preliminary Data from ALS Treatment ZFP Therapeutic Phase 2
Tweet Send to a Friend
Sangamo BioSciences, Inc. (NASDAQ: SGMO) announced today the presentation of preliminary data from the Phase 2 clinical trial of its ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
